1.Present Status and Treatment of Hyperlipidemia.
Korean Circulation Journal 1991;21(3):467-473
No abstract available.
Hyperlipidemias*
2.Managenment of hyperlipidemia.
Korean Journal of Medicine 1999;57(4):593-600
No abstract available.
Hyperlipidemias*
3.Hyperlipidemia.
Korean Journal of Medicine 2000;59(5):596-598
No abstract available.
Hyperlipidemias*
4.Childhood hyperlipidemia in Korea: a review.
Journal of the Korean Pediatric Society 1993;36(8):1049-1058
No abstract available.
Hyperlipidemias*
;
Korea*
5.Study on adjusting indexes of lipidemia of prescription TT2 of the hypertension patients with lipidemia disorder
Journal of Practical Medicine 2005;530(11):11-13
51 hypertension patients with lipidemia disorder were treated at Hospital of Military Traditional Medicine from April to September 2004. All patients were divided into 2 groups: The control group consisted of 19 patients who received Caropil 25mg tablet/ twice a day during 28 continuous days; the study group consisted of 32 patients who received a traditional recipe of TT2/per day divided into 2 times every 12 hours during 28 days. Among hypertension patients with primary lipidemia disorder and signs of phlegm wetness or and phlegm heat types, using a traditional recipe of T22/per day during continuous 28 days had effects of regulating the index of lipidemia: CT decrease of 14.9%; TG decrease of 27.5%; LDL-C decrease of 16.2%; the effects of increasing HDL-C were not significantly (increase of 6.5%).
Hypertension
;
Hyperlipidemias
6.Effect of Pantethine in the Treatment of Hyperlipidemia.
Kyung Pyo HONG ; Chung Hoo KANG ; Myoung Mook LEE ; Young Bae PARK ; Jungdon SEO ; Young Woo LEE
Korean Circulation Journal 1982;12(2):225-229
After pantethine in doses of 540 mg per day was administered for 8 weeks in 20 patients with hyperlipidemia, the serum levels of total cholesterol, triglyceride and HDL-cholesterol were compared with the pretreatment level. The serum level of total cholesterol decreased to 240+/-52 mg%[mean+/-standard deviation] after 4 weeks and 223+/-41 mg% after 8 weeks from the pretreatment level of 293+/-38 mg%(p<0.01). The serum triglyceride level also decreased to 254+/-109 mg% after 4 weeks and 239+/-114 mg% after 8 weeks from the pretreatment level of 375+/-126 mg%(p<0.01). But, there was no significant change in the serum levels of HDL-cholesterol before and after treatment (56+/-27 mg% beforAfter pantethine in doses of 540 mg per day was administered for 8 weeks in 20 patients with hyperlipidemia, the serum levels of total cholesterol, triglyceride and HDL-cholesterol were compared with the pretreatment level. The serum level of total cholesterol decreased to 240+/-52 mg%[mean+/-standard deviation] after 4 weeks and 223+/-41 mg% after 8 weeks from the pretreatment level of 293+/-38 mg%(p<0.01). The serum triglyceride level also decreased to 254+/-109 mg% after 4 weeks and 239+/-114 mg% after 8 weeks from the pretreatment level of 375+/-126 mg%(p<0.01). But, there was no significant change in the serum levels of HDL-cholesterol before and after treatment (56+/-27 mg% before treatment, 56+/-18 mg% after 4 weeks and 59+/-22 mg% after 8 weeks). Pantethine was well tolerated in most patients.
Cholesterol
;
Humans
;
Hyperlipidemias*
;
Triglycerides
7.Hyperlipidemia in kidney transplant recipients.
Dong Chan JIN ; Suk Ju AHN ; Je Young WOO ; Yong Soo KIM ; Suk Young KIM ; Eui Jin CHOI ; Yoon Sik CHANG ; Young Suk YOON ; Byung Kee BANG
Korean Journal of Nephrology 1993;12(2):156-164
No abstract available.
Hyperlipidemias*
;
Kidney*
;
Transplantation*
8.A study of relationship between hypertension and hyperlipidemia in the health screening center.
Yong Chul KIM ; Im Yu KIM ; Youn Sug CHOI ; H cheol SHIN ; Eun Sook PARK
Journal of the Korean Academy of Family Medicine 1992;13(5):410-419
No abstract available.
Hyperlipidemias*
;
Hypertension*
;
Mass Screening*
9.Recent Pharmacologic Treatment of Hyperlipidemia in Children.
Journal of Korean Society of Pediatric Endocrinology 2004;9(1):17-21
No abstract available.
Child*
;
Humans
;
Hyperlipidemias*
10.The hypocholesterolemic effect of Ganoderma lucidum in rats
Yen Thi Bach Pham ; Phan Van Dao
Journal of Medical Research 2007;52(5):30-34
Background: According to traditional medicine, Ganodermataceae has many good effects on such as anti-oxidant, liver protection, sedation, anti-tumor, treatment of dyslipidemia,... Hong chi DaLat \ufffd?[Ganoderma lucidum (HC)] is a species of Ganodermataceae. This species has two strains DL1 and DL2, was grown and used mainly in Da Lat but they had not been fully studied. Objectives: To evaluate the cholesterol lowering effect of HC in cholesterol induced hypercholesterolemic rats. Subjects and method: Rats were given orally the cholesterol 10% with 0.5g/kg body weight/day during 6 consecutive weeks in order to induce hypercholesterolemic rats. The hypocholesterolemic effect of extract of (HC) was investigated at the dose of 4g/kg administered orally in hyperlipidaemic rats after 6 weeks. Results: HC with the dose of 4g/kg significantly decreased plasma triglyceride, total cholesterol, LDL \ufffd?C levels by 24.82%, 27.41% and 54.32% respectively, but increased HDL \ufffd?C by 53.34%. The effect of HC on plasma cholesterol levels with the oral dose of 4g/kg, 12g/kg was equal to each other and to that of cholestyramin at the dose of 1.6g/kg. Conclusion: HC has hypocholesterolemic effect in rats.
Reishi
;
Hyperlipidemias
;
Rats
;